The Food and Drug Association has reviewed a "Clinical Thank You Email" in which Baxter Healthcare Corp. overstated claims about their inhibitor bypassing clotting complex FEIBA VH.
The agency ordered Baxter to stop using the e-mail and any promotions that exaggerate the drug's safety and effectiveness. "By promoting misleading safety and efficacy claims, you are potentially encouraging the unsafe use of FEIBA VH," the FDA said in the letter dated July 7.
Baxter isn't a small outfit. You'd think they would have access to their own data. Why would they exaggerate these claims? Methinks someone's in trouble.
Thursday, August 7, 2008
Subscribe to:
Post Comments (Atom)
1 comment:
Wyeth got one too...
http://www.fdanews.com/newsletter/article?articleId=108846&issueId=11798
Wonder why all the sudden scrutiny?
I'm worried that something is afoot in the insurance industry such as insurance looking for reasons to move patients from one product to another.
Post a Comment